English

Redeye: Orphazyme - Home run moves nearer (and with funding in place)

Report this content

The case for Orphazyme continues to strengthen as arimoclomol’s US early access program reinforces a raft of positive data and regulatory progress over the past year. The company is now on the verge of starting to harvest its lead project’s USD1bn-plus sales potential, with launch for NPC likely next year in both Europe and the US.

Read more and download the latest research report: http://bit.ly/37p0Ay1

Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/